MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

uinber.									<u>/</u>			
Substitute for form 1449B/PTO						Complete if Kryown						
	INFO	RMATION DIS	SCLO	SURE		Application Number		Unassigned				
STATEMENT BY APPLICANT						Filing Date		04/14/2004				
\	\ Dola	Submitted: Ap	ر ان	2004		First Named Invento	r	Sunghoon KIM				
	Pare	oubillities. Ap	// IT	, 2004		Group Art Unit		Uprassigned				
(use as	many sheets	as ne	cessary)		Examiner Name		Unassigned				
Sheet	1		of	2		Attorney Docket Numi	ber /	058333-0118				
		1										
		1			11.6	DATENY DOCUMENT	. /					
	,				0.5.	PATENT DOCUMENTS	<u>s/</u>					
Examiner Initials*	Cite No. ¹	Number		Kind Name of		Patentee or Applicant of Cited Document		of Publication of ed Document M-DD-YYYY	Pages, Columns, Lin Where Relevant Passages or Releva Figures Appear	,		
	 		\ 			/_			·			
			//			7						
F		———— <u> </u>	-74	- }(1							
		,			FORE	N PATENT DOCUME		/				
Examiner Initials*	Cite No.1		Patent mber ⁴	Document Kind Cod (Nown	e ⁵ App	Name of Patentee or dicant of Cited Documents	Ci	of Publication of ted Document IM-DD-YYYY	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	T ⁶		
LDL	A1	WO 00/7	3801	\\		W/G INSTITUTE FOR ICER RESEARCH	12-0	7-2000				
·		<u> </u>			\ \ \	·						
					__/_	<u>-</u>				•		
						NT LITERATURE DOCUM			-			
Examiner Initials*	Cite No.1	Include name of the author/in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.										
LX	A2	of the Endoth	elial M	fonocyte-activ	vating Pot	nt of the Mammalian Multi- ypetice II Cytokine", J.Biol. d Molecular Biology, Inc.	syntheta Chem. (se Complex Is Like 1997), Vol. 272, No	ely to be the Precursor b. 51, pp. 32573-32579,			
	A3	BEHRENSDORF, H. et al. The endothelial monocyte-activating polypeptide II (EMAP II) is a substrate for caspa: FEBS Lett., (2000), Vol. 466, pp. 143-147, Federation of European Biochemical Societies.								1		
	A4	KAO, J. et al. "A Peptide Derived from the Amino Terminus of Endothelial-Monocyte-activating Polypeptide II Modulates Mononuclear and Polymorphonuclear Leukocyte Functions, Defines an Apparently Novel Cellular Interaction Site, and Induces an Acute Inflammatory Response", J. Biol. Chem. (1994), Vol. 269, No. 13, pp. 9774-9782, The American Society for Bigchemistry and Molecular Biology, Inc. KAO, J. et al. "Endothelial Monocyte-activating Polypeptide II: A Novel Tumor-Derived Polypeptide That Activates Host-Response Mechanisms", J. Biol. Chem. (1992), Vol. 267, No. 28, pp. 20239-20247, The American Society for Biochemistry and Molecular Biology, Inc.										
	A5											
	A6 KAO, J et al. "Characterization of a Novel Tumor-derived Cytokine: Endothelial-Monocy (1994), Vol. 269, No. 40, pp. 25108-25119, The American Society for Biochemistry and I							nistry and Molecula	ar Biology, Inc.			
	A7	KN/ES, U.E. et al., "Regulation of endothelial monocyte-activating polypepthie II release by apoptosis", Proc. Natl. Acad. Sci. USA (1998), Vol. 95, pp. 12322-12337.										
	A8	SCHWARZ, M.A. et al., "Endothelial-Monocyte Activating Polypeptide II, A Novel Antitumor Cytokine that Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells", J. Exp. Med. (1999) Vol. 190, No. 3, pp. 341-352, The Rockefeller University Press.										
V	A ⁴⁹	TAS, M.P.R. a Vol. 28, No. 8	and M , pp. 8	URRAY, J.C. 337-841, 1996	, "Endothe 6 Elsevier	elial-Monocyte-Activating P Science Ltd.	olypeptic	de II", Int. J. Bioche	em. Cell. Biol. (1996),			
		// .										
Examiner Signature		(m)	1	ret			Date Cons	sidered	1/28/05			
AFVALM	(EB. 1-4	di il reference co				,		<u> </u>				

considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-lettler code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ²Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** Unassigned STATEMENT BY APPLICANT Filing Date 04/14/2004 First Named Inventor Sunghoon KIM Date Submitted: April 14, 2004 Group Art Unit Unassigned use as many sheets as necessary) **Examiner Name** Unassigned Sheet of 2 **Attorney Docket Number** 058333-0118

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), folume-issue number(s), publisher, city and/or country where published. SCHLUESENER, H.J. et al., "Localization of Endothelial-Monocyte-Activating Polypeptide II (EMAP II), a Novel Proinflammatory Cytokine, to Lesions of Experimental Autoimmune Encephalomyeritis, Neuritis, and Uveltis", GLIA (1997), Vol. 20, pp. 365-372, Wiley-Liss, Inc.					
ul	A10						
	A11	BERGER, A.C. et al., "Endothelial Monocyte-Activating Polypeptide II, a Tumor-Derived Cytokine That Plays an Important Role in Inflammation, Apoptosis, and Angiogenesis", J. Immunother. (2000), Vol. 23, No. 5, pp. 519-527, Lippincott, Williams and Wilkins, Inc.					
	A12	KO, Y.G. et al., "A Cotactor of tRNA Synthetase, p43, is Secreted to Up-regulate Proinflammatory Genes", J. Biol. Chem. (2001), Vol. 276, No. 25, pp. 23028-23033, The American Bociety for Blochemistry and Molecular Biology, Inc.	T				
V	A13	PARK, S.G. et al., "Precursor of Pro-apoptotic Cytokine Modulates Aminoacytation Activity of IRNA Synthetase", J. Biol. Chem. (1999), Vol. 274, No. 24, pp.16873-16676, The American Society for Biochemistry and Molecular Biology, Inc.					

Duplicate

Examiner Signature M Date Considered 1/8/65

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Crief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.